PHEOCHROMOCYTOMA

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This study tests a combination of two drugs—Lutathera (a targeted radiation therapy) and olaparib (a PARP inhibitor)—in children and teens aged 3 to 18 with solid tumors that have come back or not responded to standard treatment. The goal is to find the safest dose and see if the…

This study tests a radioactive drug called Lu-177-DOTATATE in people with rare tumors (pheochromocytoma or paraganglioma) that cannot be surgically removed. The goal is to see if the drug can slow or stop tumor growth and to check its safety. Participants receive four doses about…

This study tests a new drug that delivers radiation directly to cancer cells in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paraganglioma that have already been treated with radiation therapy. The drug works by attaching to a protein found on t…

This study tests a new treatment called [212Pb]VMT-α-NET for people with advanced tumors that have a specific marker (SSTR2). The treatment delivers targeted radiation to kill cancer cells while sparing healthy tissue. The study involves up to 300 adults with neuroendocrine tumor…

This study tests a radioactive drug called I-MIBG in people with neuroblastoma or related tumors that have not responded to standard treatments. The drug targets cancer cells and delivers radiation directly to them. Researchers want to see if it can shrink tumors and how safe it …

This study aims to see if special PET scans using different radioactive tracers can accurately find and stage neuroblastoma and pheochromocytoma/paraganglioma tumors. About 30 people aged 1 to 70 with suspected or confirmed disease will receive an injection of a tracer and then h…

This study aims to develop better methods for finding and understanding pheochromocytoma and paraganglioma, rare tumors that can cause severe high blood pressure, stroke, or heart attack. Researchers will use blood tests, advanced imaging, and genetic analysis in up to 3,000 part…

This study aims to find the genes that cause pheochromocytoma and paraganglioma, rare tumors of the nervous system. Researchers will analyze DNA from up to 2,000 patients and their family members to link specific genetic changes to tumor development. The goal is to improve geneti…

This study tests a new PET scan tracer (18F-FluorThanatrace) to measure PARP-1 protein levels in people with rare adrenal tumors called pheochromocytoma or paraganglioma. About 30 adults will get one scan before their usual treatment. The scan results won't change their care—the …

This study aims to better understand how adrenal tumors develop and to evaluate new treatment options for adrenal cancer. Researchers will enroll 500 people who have an adrenal tumor seen on imaging. The goal is to improve care for patients with these rare tumors.

This study is creating a large database to collect information about people with rare diseases like amyloidosis, sarcoidosis, and many others. Researchers will track participants' health, treatments, and outcomes over time to better understand these conditions. The goal is to imp…